Mar 11th 2013 - Edison Investment Research today published a report on quickview entitled "Trials And Sales". In summary, the report says:
Cytori had 2012 product revenues of $8.7m plus development contracts of $5.8m. The PureGraft system for autologous fat grafting and aesthetic body contouring has FDA 510(k) and EU CE mark approval and sold 5,000 units, up 46%. The Japanese approval of the Celution system for enriching adipose stem populations increased sales by $2m in Q4. Product sales in 2013 could be over $15m in the EU and Japan. The Phase II ATHENA chronic heart disease trial reports H114.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »
